Research programme: induced pluripotent stem cell therapeutics - Center for iPS Cell Research Application/Takeda

Drug Profile

Research programme: induced pluripotent stem cell therapeutics - Center for iPS Cell Research Application/Takeda

Alternative Names: iPS cell based therapeutics - CiRA/Takeda; NGLY1 deficiency therapeutic - CiRA/Takeda/RIKEN

Latest Information Update: 13 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Center for iPS Cell Research and Application; Takeda
  • Developer Center for iPS Cell Research and Application; RIKEN; Takeda
  • Class Stem cell therapies
  • Mechanism of Action Stem cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Cancer; Diabetes mellitus; Heart failure; Inborn genetic disorders; Neurological disorders

Most Recent Events

  • 31 Mar 2017 Center for iPS Cell Research and Application, Takeda and RIKEN agree to co-develop induced stem cell therapeutics in Japan for Inborn genetic disorders
  • 31 Mar 2017 Early research in Inborn genetic disorders in Japan (Parenteral)
  • 17 Apr 2015 Early research in Cancer in Japan (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top